Biotech

Latest Articles

Basilea scores $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's job developing new antifungals has gotten a significant improvement coming ...

Capricor offers Europe civil rights to late-stage DMD treatment for $35M

.Having already scooped up the U.S. civil liberties to Capricor Therapies' late-stage Duchenne muscl...

FDA junks adcomm for Applied's uncommon ailment medicine

.After dismissing the decision date for Applied Therapeutics' metabolic problem drug govorestat, the...

Novo inks $600M NanoVation offer to analyze genetic drugs ex-liver

.Novo Nordisk is continuing its own press in to genetic medications, agreeing to compensate NanoVati...

Innovent links cytokine to colon cancer cells reactions

.Innovent Biologics has produced the scenario that its own checkpoint inhibitor-cytokine combination...

Merck, Daiichi ADC strikes goal in period 3 bronchi cancer cells research study

.A period 3 test of Daiichi Sankyo as well as Merck &amp Co.'s HER3-directed antibody-drug conjugate...

Rakovina deepens AI concentrate with collab to select cancer intendeds

.Five months after Rakovina Therapies turned toward artificial intelligence, the cancer-focused biot...

Ascendis' dwarfism medicine favorites in period 3, intimidates BioMarin

.Ascendis Pharma has actually emerged as a potential danger to BioMarin's Voxzogo, reporting phase 3...

Despite ph. 3 miss out on, Alkeus views road in advance for eye health condition possession

.Though Alkeus Pharmaceuticals' oral eye illness asset failed to significantly minimize geographical...

Kairos goes social along with $6M IPO to cash tests of cancer drug

.Along with a trio of biotechs hitting the Nasdaq on Friday, it was actually simple to overlook a sm...

Vaccine as well as Keytruda combo reliable in squamous cell cancer

.Immune system checkpoint inhibitors are actually the superheroes of cancer cells therapy. Medicatio...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of substantial management hirings, shootings as ...

Regeneron's Opdualag rival presents 57% feedback fee

.Regeneron is actually back along with long-lasting follow-up for its own LAG-3 prevention and PD-1 ...

AstraZeneca messages records on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early consider the functionality of its in-house antibody-drug conjugate ...

iTeos- GSK's TIGIT star reveals relevant renovation

.After revealing a phase 3 launch based on good midstage end results, iTeos and also GSK are finally...

More collective FDA can speed up rare ailment R&ampD: report

.The FDA should be much more open as well as joint to discharge a surge in approvals of unusual cond...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It's an uncommonly occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Rehabs al...

Atea's COVID antiviral falls short to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has actually fallen short yet another COVID-19 test, but the biotec...

Neurocrine's quote to conserve schizophrenia prospect neglects

.Neurocrine Biosciences' schizophrenia course pivot has actually neglected. The biotech was unable t...

Sanofi spends $110M upfront for late-stage radioligand therapy

.Sanofi has actually brought in an overdue entry to the radioligand event, spending 100 million euro...